GlassScriptPhysician profile
Lisa A Steinmueller
NPI 1265705032
$7,085.24
in general payments reported to CMS, 2019-2025
29 companies · $1,247 in 2025
The $1,247 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,453 · 2022: $1,694 · 2023: $1,864 · 2024: $828 · 2025: $1,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,937.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $883.90 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $839.25 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $651.87 | 2022-2025 | |
| Amarin Pharma, INC. | $629.70 | 2021-2023 | |
| Abbvie INC. | $545.85 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $398.14 | 2021-2023 | Brilinta, Farxiga, Breztri |
| Abiomed | $343.14 | 2025 | |
| Amgen INC. | $326.70 | 2022-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $309.19 | 2021-2024 | Trintellix |
| Merck Sharp & Dohme LLC | $283.15 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $279.38 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.18 | 2021-2025 | Jardiance, Synjardy |
| Pfizer INC. | $196.32 | 2021-2024 | |
| Janssen Biotech, INC. | $181.25 | 2024-2025 | Tremfya |
| Sanofi-Aventis U.S. LLC | $166.14 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $165.13 | 2021-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $145.69 | 2024-2025 | Lifevest |
| Genzyme Corporation | $130.02 | 2025 | |
| Janssen Scientific Affairs, LLC | $93.76 | 2022 | |
| Insmed, INC. | $65.12 | 2023 | Arikayce |
| Lundbeck LLC | $51.23 | 2025 | Rexulti |
| Gilead Sciences, INC. | $31.50 | 2025 | |
| Dexcom, INC. | $29.07 | 2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $28.61 | 2023 | Arexvy, Trelegy Ellipta |
| Baxter Healthcare | $24.69 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Otsuka America Pharmaceutical, INC. | $24.56 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $22.90 | 2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $21.62 | 2025 | Fanapt |
| Novartis Pharmaceuticals Corporation | $19.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Steinmueller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.